Endocyte Inc (ECYT) 6.58 $ECYT
What Biotech Investors Need to Know About Phase 2 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - 2 hrs 43 mins ago
Phase 2 trials occupy an interesting place in a clinical development plan. Theoretically, phase 2 is just the next step after phase 1, advancing a drug to tests of efficacy after safety and tolerability are established. Phase 2 is generally when a...
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:44AM CDT
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Endocyte Shares Sink on DSMB Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 3:45PM CDT
Endocyte (ECYT) shares tumbled 61.9% after the announcement by the DSMB to stop the PROCEED trial evaluating Vynfinit (vintafolide).
Today's Dead Cat Bounce Stock: Endocyte (ECYT)
at The Street - Mon May 05, 8:45AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun May 04, 8:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company May 2 Weekly Loss Endocyte $6.62 63% Gogo ...
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 7:35PM CDT
Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the...
Endocyte
at Investor's Business Daily - Fri May 02, 5:58PM CDT
Endocyte (ECYT) and its big-pharma partner Merck (MRK) ended trials of ovarian-cancer treatment Vynfinit after interim analysis showed no improvement in patients' progression-free survival. Endocyte shares fell 62%. Merck fell 2%.
Down 62%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Endocyte shares were hammered today, after the data safety monitoring board halted a phase 3 trial for its flagship drug after concluding that the drug would not achieve its primary endpoint. Vintafolide was being tested for platinum-resistant...
Nasdaq stocks posting largest volume increases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
LinkedIn and Skullcandy are big market movers
AP - Fri May 02, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Today's 3 Biotech Blow-Ups
Todd Campbell, The Motley Fool - Motley Fool - Fri May 02, 1:40PM CDT
While the Motley Fool believes investing should be a long term affair, investors should be aware when companies of interest make big moves higher or lower. Such big moves are usually due to important developments that could significantly influence...
Merck's Drug Failure, Chevron's Earnings Plunge Lead the Dow's Fall
Dan Carroll, The Motley Fool - Motley Fool - Fri May 02, 1:38PM CDT
The market is on the way to closing out the week in the red despite strong numbers in the government's Apriil jobs report. The Dow Jones Industrial Average was down 52 points as of 2:30 p.m. EDT, with most blue-chip stocks in the red and the...
Why Endocyte, Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
What Biotech Investors Need to Know About Phase 2 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - 2 hrs 43 mins ago
Phase 2 trials occupy an interesting place in a clinical development plan. Theoretically, phase 2 is just the next step after phase 1, advancing a drug to tests of efficacy after safety and tolerability are established. Phase 2 is generally when a...
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:44AM CDT
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Endocyte Shares Sink on DSMB Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 3:45PM CDT
Endocyte (ECYT) shares tumbled 61.9% after the announcement by the DSMB to stop the PROCEED trial evaluating Vynfinit (vintafolide).
Today's Dead Cat Bounce Stock: Endocyte (ECYT)
at The Street - Mon May 05, 8:45AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun May 04, 8:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company May 2 Weekly Loss Endocyte $6.62 63% Gogo ...
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 7:35PM CDT
Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the...
Endocyte
at Investor's Business Daily - Fri May 02, 5:58PM CDT
Endocyte (ECYT) and its big-pharma partner Merck (MRK) ended trials of ovarian-cancer treatment Vynfinit after interim analysis showed no improvement in patients' progression-free survival. Endocyte shares fell 62%. Merck fell 2%.
Down 62%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Endocyte shares were hammered today, after the data safety monitoring board halted a phase 3 trial for its flagship drug after concluding that the drug would not achieve its primary endpoint. Vintafolide was being tested for platinum-resistant...
Nasdaq stocks posting largest volume increases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
LinkedIn and Skullcandy are big market movers
AP - Fri May 02, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Today's 3 Biotech Blow-Ups
Todd Campbell, The Motley Fool - Motley Fool - Fri May 02, 1:40PM CDT
While the Motley Fool believes investing should be a long term affair, investors should be aware when companies of interest make big moves higher or lower. Such big moves are usually due to important developments that could significantly influence...
Merck's Drug Failure, Chevron's Earnings Plunge Lead the Dow's Fall
Dan Carroll, The Motley Fool - Motley Fool - Fri May 02, 1:38PM CDT
The market is on the way to closing out the week in the red despite strong numbers in the government's Apriil jobs report. The Dow Jones Industrial Average was down 52 points as of 2:30 p.m. EDT, with most blue-chip stocks in the red and the...
Why Endocyte, Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
